表紙
市場調査レポート

世界の子宮頚部癌ワクチンの市場機会 (2020年)

Global Cervical Cancer Vaccine Market Opportunities, 2020

発行 Pharmaion 商品コード 346836
出版日 ページ情報 英文 105 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
世界の子宮頚部癌ワクチンの市場機会 (2020年) Global Cervical Cancer Vaccine Market Opportunities, 2020
出版日: 2015年12月11日 ページ情報: 英文 105 Pages
概要

子宮頚部癌は主に、性交渉を通じてヒトパピローマウイルス (HPV) に感染することで発症します。HPVのウイルス株のうち、HPV 16とHPV 18が子宮頚部癌の発症要因となっています。子宮頚部癌ワクチンは、癌に対する人体の免疫系を刺激・強化するための生物学的製剤です。先進国・途上国を問わず、不適切な性交渉が (特に青少年層で) 増加したことと、HPVワクチンの接種率が低下したことから、9〜26歳の女性の子宮頚部癌発症件数が増加しており、それが子宮頚部癌ワクチン市場の成長促進につながっています。世界の子宮頚部癌ワクチンの市場規模は、2020年には16億米ドルに達する見通しです。

当レポートでは、世界の子宮頚部癌ワクチンの市場について分析し、全体的な市場規模・シェアの動向見通し (通算11年間分) や、地域別の詳細動向、規制・政策環境、主要企業のプロファイル、市場構造の変化と新たな市場機会、関係者への提言といった内容を取りまとめてお届けいたします。

第1章 製品概要

第2章 調査手法

第3章 アナリストの見解

第4章 世界の子宮頚部癌患者の疫学

第5章 世界の子宮頚部癌ワクチン市場の展望

  • 市場規模とその予測
    • 金額ベース
  • 市場シェアとその予測
    • 地域別 (米国、EU諸国、その他)
  • 企業別市場シェア (Merck & Co., Inc.、GlaxoSmithKline plc、Xiamen Innovax Biotech Co., Ltd.)

第6章 米国市場

  • 市場規模とその予測
    • 金額ベース
    • 数量ベース
  • 市場シェアとその予測
    • 企業別 (Merck & Co., Inc.、GlaxoSmithKline plc)
  • 子宮頚部癌患者の疫学

第7章 欧州市場の展望

  • 市場規模とその予測
    • 金額ベース
    • 数量ベース
  • 市場シェアとその予測
    • 企業別 (Sanofi Pasteur MSD、GlaxoSmithKline plc)
  • 子宮頚部癌患者の疫学

第8章 他の国々 (RoW) の市場の展望

  • 市場規模とその予測
    • 金額ベース
  • 市場シェアとその予測
    • 企業別 (GlaxoSmithKline plc、Merck Sharpe & Dome、Xiamen Innovax Biotech Co., Ltd.)

第9章 市場のダイナミクス

  • 市場促進要因
  • 市場の課題

第10章 市場の傾向と発展

  • 新製品の開発
  • 患者支援プログラム
  • ヒトパピローマウイルス (HPV) ワクチン投与件数の低下
  • 薬剤師の関与の拡大

第11章 競争環境

  • Merck & Co., Inc.
    • 企業概要
    • 規制の概要:Gardasil
    • 治験概況:Gardasil
  • GlaxoSmithKline plc
    • 企業概要
    • 規制の概要:Cervarix
    • 治験概況:Cervarix
  • Xiamen Innovax Biotech Co., Ltd.

第12章 戦略的提言

図表一覧

目次

Cervical cancer is mainly caused by Human Papilloma Virus (HPV) infection transmitted via sexual contact with an HPV-infected person. Two strains of HPV that are responsible for causing cervical cancer are HPV 16 and HPV 18. Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Increasing rate of unprotected sex, especially among adolescents, across various developed as well as developing regions, is resulting in growing incidences of cervical cancer, globally. As a result, an increasing number of people, especially females in the age group of 9-26 years, are opting for cervical cancer vaccines. Moreover, reduction in the number of recommended doses of HPV immunisation from three to two, which enhances the uptake of vaccine among a large adolescent female population, is anticipated to drive the global cervical cancer market during 2015 - 2020.

According to Pharmaion report, “Global Cervical Cancer Vaccine Market Opportunities, 2020”, global cervical cancer vaccine market is anticipated to cross US$ 1.6 billion by 2020 on account of increasing immunization programs for HPV vaccination, rising prevalence of cervical cancer and favorable government initiatives to increase disease awareness. However, the unavailability of HPV vaccines in some regions of the world, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market. In 2014, the United States was the largest consumer of cervical cancer vaccines, and the country is expected to continue its dominance through 2020 owing to the launch of a nine-valent HPV vaccine, Gardasil 9, in 2014 which protects against the infection of all 9 types of HPV, as compared to Gardasil that protects against only four HPV types. Majorly, two US FDA approved HPV vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe.

“Global Cervical Cancer Vaccine Market Opportunities, 2020” report elaborates following aspects related to global cervical cancer vaccine market:

  • Global Cervical Cancer Vaccine Market Size, Share & Forecast
  • Segmental Analysis - By Region & By Company
  • Policy & Regulatory Landscape
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

  • To identify the on-going trends and anticipated growth in the next five years
  • To gain competitive knowledge of leading market players
  • To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer's specific needs

Table of Contents

1. Product Overview

2. Analyst View

3. Research Methodology

4. Global Cervical Cancer Patient Epidemiology

5. Global Cervical Cancer Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Region (United States, European Union & ROW)
  • 5.3. By Company (Merck & Co., Inc., GlaxoSmithKline plc & Xiamen Innovax Biotech Co., Ltd.)

6. United States Cervical Cancer Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
    • 6.1.2. By Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Company (Merck & Co., Inc. & GlaxoSmithKline plc)
  • 6.3. US Cervical Cancer Patient Epidemiology

7. Europe Cervical Cancer Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
    • 7.1.2. By Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Company (Sanofi Pasteur MSD & GlaxoSmithKline plc)
  • 7.3. Europe Cervical Cancer Patient Epidemiology

8. ROW Cervical Cancer Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Company (GlaxoSmithKline plc, Merck Sharpe & Dome and Xiamen Innovax Biotech Co., Ltd.)

9. Market Dynamics

  • 9.1. Drivers
  • 9.2. Challenges

10. Market Trends & Developments

  • 10.1. New Product Development
  • 10.2. Patient Assistance Program
  • 10.3. Reduced HPV Vaccine Dosage
  • 10.4. Expanding Involvement of Pharmacists

11. Competitive Landscape

  • 11.1. Merck & Co., Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Regulatory Footprint: Gardasil
    • 11.1.3. Clinical Highlights: Gardasil
  • 11.2. GlaxoSmithKline plc
    • 11.2.1. Company Overview
    • 11.2.2. Regulatory Footprint: Cervarix
    • 11.2.3. Clinical Highlights: Cervarix
  • 11.3. Xiamen Innovax Biotech Co., Ltd.

12. Strategic Recommendations

List of Figures

  • Figure 1: Global Estimated Incidence and 5-Year Prevalence of Cancer of Cervix Uteri, By Number of Cases, 2012
  • Figure 2: Estimated Incidence of Cancer of Cervix Uteri, By Region, By Number of Cases, 2012
  • Figure 3: Global Cervical Cancer Vaccine Market Size, By Value, 2010-2020F (USD Million)
  • Figure 4: Global Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
  • Figure 5: Global Cervical Cancer Vaccine Market Share, By Company, By Volume, 2010-2020F
  • Figure 6: United States Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
  • Figure 7: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2012
  • Figure 8: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2014
  • Figure 9: United States Gardasil and Cervarix Vaccine for Children, Average Selling Price (ASP), 2010-2014, (USD/Dose)
  • Figure 10: United States Gardasil and Cervarix Vaccine for Adults Average Selling Price (ASP), 2010-2014, (USD/Dose)
  • Figure 11: United States Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
  • Figure 12: United States High School Female Students Sexual Dating Violence, By Percentage, By Grade, 2013
  • Figure 13: United Sates Estimated Incidence of Cervix Uteri Cancer and Mortality, By Number of Cases, 2012, 2015E & 2020F
  • Figure 14: European Union Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
  • Figure 15: Germany Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 16: Germany Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
  • Figure 17: Italy Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 18: Italy Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
  • Figure 19: France Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 20: France Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
  • Figure 21: United Kingdom Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 22: United Kingdom Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence and 5-year Prevalence
  • Figure 23: European Union Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
  • Figure 24: European Union Cervix Uteri Cancer Incidence and Mortality, By Number of Cases, 2012, 2015E & 2020F
  • Figure 25: Rest of the World Cervical Cancer Vaccine Market Size, By Value (USD Million), 2010-2020F
  • Figure 26: Japan Major Events Related to HPV Vaccines, 2010-2013
  • Figure 27: Japan Major Events Related to HPV Vaccines, 2013-2015
  • Figure 28: Australia HPV 3 Dose Vaccine Coverage for Females of Age 15 years, By State, By Number, 2014
  • Figure 29: Australia HPV 3-Dose Vaccine Coverage for Females of Age 15 years, By State, By Percentage, 2012-14
  • Figure 30: ROW Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
  • Figure 31: Middle East and North Africa Estimated Incidence of Cancer of Cervix Uteri, By Number of Cases, 2012, 2015E & 2020F

List of Tables

  • Table 1: Process of Development of Cervical Cancer after an HPV Infection
  • Table 2: Global HPV Vaccines and their HPV Types
  • Table 3: European Union Recommended HPV Immunization, By Country, By Age
  • Table 4: Partial List of HPV Vaccination Practices across European Union
  • Table 5: Cervarix and Gardasil Prices offered by GAVI, By Dose, By Year
  • Table 6: Cervical Cancer Vaccine in Pipeline
  • Table 7: Europe Two-dose HPV Vaccines Schedule Marketing Authorization, By Year, By Age Group
  • Table 8: Countries with Regulatory Approval of Gardasil
  • Table 9: Key Results from Phase III Trials of Gardasil Vaccine
  • Table 10: Key Results from Phase III Trials of Cervarix Vaccine
Back to Top